07:00 , Sep 19, 2016 |  BC Week In Review  |  Company News

Lundbeck neurology, generics news

The EU General Court upheld a decision from the European Commission to fine Lundbeck for anticompetitive activity related to Lundbeck’s antidepressant Celexa citalopram. The court said that the commission correctly found that Lundbeck’s agreements...
07:00 , Apr 21, 2016 |  BC Innovations  |  Targets & Mechanisms

Structural SERT-ainty

The publication this month of the crystal structure of the serotonin transporter unquestionably marked a technical watershed, and solved long-asked questions about why similar compounds bind the protein differently. Historically, the target revolutionized depression, spawning the...
07:00 , Apr 18, 2016 |  BC Week In Review  |  Company News

Epic Pharma, Humanwell Healthcare Group, PuraCap Pharmaceutical LLC deal

Humanwell and PuraCap will acquire generic company Epic for $550 million. Epic’s assets include generics of cardiovascular drug amlodipine, marketed as Norvasc by Pfizer Inc. (NYSE:PFE, New York, N.Y.); depression drug citalopram, marketed...
07:00 , Jul 17, 2014 |  BC Innovations  |  Distillery Techniques

Technology: Markers

Approach Summary Licensing status Publication and contact information Markers Monitoring microRNA-1202 (miR-1202) expression to predict antidepressant treatment response Cell culture and patient sample studies suggest monitoring miR-1202 expression could...
07:00 , Jun 19, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Alzheimer's disease (AD) Serotonin (5-HT) transporter (SLC6A4; SERT) Mouse and human studies suggest selective serotonin reuptake inhibitors...
07:00 , Sep 9, 2013 |  BC Week In Review  |  Company News

Lundbeck neurology news

H. Lundbeck filed an appeal in the EU General Court of a June 19 decision from the European Commission to fine Lundbeck €93.8 million ($124 million) for anticompetitive activity related to Lundbeck's antidepressant Celexa...
07:00 , Jun 24, 2013 |  BC Week In Review  |  Company News

Actavis, Lundbeck, Merck KGaA, Ranbaxy, Xellia Pharmaceuticals A/S, Zoetis neurology news

The European Commission fined H. Lundbeck €93.8 million ($125 million) after ruling that deals with four generic companies for Lundbeck's antidepressant Celexa citalopram violated competition law. The commission said that after Lundbeck's basic patents...
08:00 , Nov 5, 2012 |  BioCentury  |  Strategy

Racing to rebuild AZ

AstraZeneca plc's new CEO Pascal Soriot has not yet detailed his vision for the company, but comments last month on his first call with investors coupled with an early move to halt the company's planned...
07:00 , Jul 30, 2012 |  BC Week In Review  |  Company News

Lundbeck neurology news

H. Lundbeck said it received from the European Commission a statement of objections regarding deals with four generic companies for Lundbeck's antidepressant Celexa citalopram. Lundbeck, which did not disclose the contents of the statement...
08:00 , Dec 5, 2011 |  BioCentury  |  Strategy

Lundbeck psyched up

H. Lundbeck A/S's deal with Otsuka Pharmaceutical Co. Ltd. for two late-stage programs is designed to take the Danish pharma beyond replacing patent-related revenue losses, giving it products to establish a foothold in the U.S....